Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects

Completed · Phase 1

Conditions studied: N/A - Healthy Subjects

In brief

The purpose of this study is to assess the effect of Atenolol 100 mg on the Pharmacokinetics (PK) of Apixaban and the effect of Apixaban 10 mg on the PK of Atenolol in Healthy subjects.

Key facts

Study ID

NCT02262533

Run by

Bristol-Myers Squibb

People needed

15

Starts

2007-06-01

Expected to finish

2007-06-01

Last updated by the study team

2015-08-10

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiogram (ECGs), and clinical laboratory determinations

You may not qualify if…

• Any significant acute or chronic medical illness, history of hypotension, history or evidence of abnormal bleeding or coagulation disorders, significant head injury within the last 2 years

Where it is running

• Bms Clinical Research Center — Hamilton, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.